The aim of this study is to test Cenicriviroc (CVC) as a means to reduce the severity of the
lung disease COVID-19 caused by an infection with SARS-CoV-2. The safety of CVC, when
administered to COVID-19 patients, will also be assessed. Furthermore, the clinical trial
aims to answer the question of whether patients with pre-existing conditions, who have an
increased risk of severe COVID-19 progression, benefit more and particularly from CVC. CVC is
an orally available dual inhibitor of the chemokine receptors CCR2 and CCR5, which is
expected to reduce (hyper-) inflammation in COVID-19.
The main goal of the study is to determine whether CVC helps increase the number of patients
who are symptom-free and not hospitalized after 14 days compared to a placebo. Approximately
66.7% of the patients enrolled in the study will receive CVC and 33.3% will get an optically
identical pill (placebo).
Subjects will be assessed daily while hospitalized. Discharged patients will be asked to
attend study visits at Days 8, 15, 22, and 29 and 85. All subjects will undergo a series of
clinical, safety, and laboratory assessments. Blood samples and oropharyngeal (OP) swabs will
be obtained on Day 1; 3, 5 (while hospitalized); and Day 8, 15 and 29 (if able to return to
clinic or still hospitalized). The presence of anti-SARS-CoV-2 antibodies will be determined
on Days 29 and 85.